Despite concerted efforts in recent years, clinical studies focusing on HER2-targeted therapy for HER2-positive NSCLC have yielded unsatisfactory results, with such NSCLC receiving only limited clinical benefit from targeted therapy(Uy, Merkhofer, & Baik, 2022). Here, ERBB2 is linked to non-small cell lung carcinoma.